Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ:CRVS
Want to see CRVS full AI Analyst Report?
CRVS Stock Chart & Stats
$16.74
-$0.10(-1.74%)
At close: 4:00 PM EST
$16.74
-$0.10(-1.74%)
Day’s Range― - ―
52-Week Range$3.55 - $26.95
Previous CloseN/A
Volume202.27K
Average Volume (3M)1.70M
Market Cap
$1.04B
Enterprise Value$1.00B
Total Cash (Recent Filing)$236.71M
Total Debt (Recent Filing)$834.00K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding84,090,420
10 Day Avg. Volume2,317,767
30 Day Avg. Volume1,704,917
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.26K
Enterprise Value/Ebitda-21.18
Forecast
1Y Price Target
$31.60Price Target Upside88.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase I AD EfficacyRobust, statistically significant cohort-level efficacy in atopic dermatitis provides durable clinical proof‑of‑concept for soquelitinib. A clear early efficacy signal supports dose selection, prioritization of indications, and improves the odds of positive outcomes in larger, registrational trials over the next 2–3 years.
Durable Treatment ResponsesSustained remission without rebound suggests intermittent dosing potential and differentiated long‑term patient benefit. Durable responses reduce chronic treatment burden, strengthen commercial positioning versus continuous therapies, and can materially improve cost‑effectiveness and payer acceptance if confirmed in larger trials.
Improved Cash RunwayA meaningful financing extends operational runway through planned mid‑ and late‑stage readouts, lowering near‑term solvency risk and enabling multi‑indication development. This capital buffer increases the probability management can complete planned trials without immediate dilutive recapitalization.
Bears Say
No Revenue / Persistent LossesAs a clinical‑stage biotech, the company lacks recurring revenue and reports widening TTM losses and cash burn. Continued negative operating and free cash flow means long‑term viability depends on successful clinical outcomes or additional financing, keeping solvency and dilution risk elevated over the coming quarters.
Small Early CohortsEfficacy drawn from small, early cohorts increases binary development risk: results may not scale in randomized Phase II/III populations. Reliance on small sample sizes makes program value contingent on successful larger readouts, elevating execution and clinical development uncertainty for months to years.
Finite Runway Vs Ambitious PipelineAlthough financing materially extended runway, simultaneous Phase II/III programs and international studies raise near‑term cash consumption. If trial timelines slip or enrollment costs rise, the company may face additional fundraising or reprioritization, creating execution and dilution risk over the next 12–24 months.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc.’s price range in the past 12 months?
Corvus Pharmaceuticals Inc. lowest stock price was $3.55 and its highest was $26.95 in the past 12 months.
What is Corvus Pharmaceuticals Inc.’s market cap?
Corvus Pharmaceuticals Inc.’s market cap is $1.04B.
When is Corvus Pharmaceuticals Inc.’s upcoming earnings report date?
Corvus Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 71 days.
How were Corvus Pharmaceuticals Inc.’s earnings last quarter?
Corvus Pharmaceuticals Inc. released its earnings results on May 07, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.008.
Is Corvus Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc.’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc. pay dividends?
Corvus Pharmaceuticals Inc. does not currently pay dividends.
What is Corvus Pharmaceuticals Inc.’s EPS estimate?
Corvus Pharmaceuticals Inc.’s EPS estimate is -0.16.
How many shares outstanding does Corvus Pharmaceuticals Inc. have?
Corvus Pharmaceuticals Inc. has 84,090,420 shares outstanding.
What happened to Corvus Pharmaceuticals Inc.’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 6.58%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.60 (88.77% Upside)
$31.60 (88.77% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $83.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.57%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
325.98%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
CRVS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$31.60
▲(88.77% Upside)
Technical Analysis
Ownership Overview
22.33% Insiders
11.59% Mutual Funds
45.57% Other Institutional Investors
8.38% Public Companies and
Individual Investors